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Abstract: Subacute sclerosing panencephalitis is a progressive neurodegenerative disease. It 
usually occurs 7–10 years after measles infection. The clinical course is characterized by progres-
sive cognitive decline and behavior changes followed by focal or generalized seizures as well 
as myoclonus, ataxia, visual disturbance, and later vegetative state, eventually leading to death. 
It is diagnosed on the basis of Dyken’s criteria. There is no known cure for subacute sclerosing 
panencephalitis to date, but it is preventable by ensuring that an effective vaccine program for 
measles is made compulsory for all children younger than 5 years in endemic countries.
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Introduction
Subacute sclerosing panencephalitis, commonly known as SSPE, is a progressive neu-
rodegenerative disease caused by the persistence of measles infection commonly seen 
in children and young adults.1 SSPE was previously known as Dawson’s inclusion body 
encephalitis as Dawson in 1933 and 1934 reported cellular inclusions in the cerebral 
lesions of patients with SSPE, thus resulting in this disease being labeled as Dawson 
inclusion body encephalitis.2 Ten years later, Brain et al3 reported similar conditions 
with further case reports, and later, the term SSPE was coined. Electron microscopic 
evidence of paramyxovirus was established between 1967 and 1969.4
Measles is a highly contagious RNA virus of the paramyxoviridae family and the 
genus morbillivirus. It is an airborne disease and transmitted via nasopharyngeal drop-
lets. The virus is highly lymphotropic, affecting dendritic cells, alveolar macrophages, 
and subsets of B and T cells in the lymphoid tissue of the lower respiratory tract, and 
later, it infiltrates the epithelium of the upper respiratory tract. Acute complications 
include otitis media, pneumonia, diarrhea, and postinfectious encephalitis.5 Neurologi-
cal complications of measles involve post-measles encephalitis, measles inclusion body 
encephalitis, transverse myelitis, and SSPE.6 The risk of serious complications and 
death is increased in children younger than 5 years and adults older than 20 years.7 This 
disease is preventable, and immunization against measles via live attenuated vaccine 
has been available for more than 45 years.8
SSPE usually occurs 7–10 years after measles infection, but the latency varies 
from 1 month to 27 years.9 A shorter latency has been reported in intrafamilial cases 
of SSPE as well as in children who were affected at an earlier (<2 years) age such that 
the incidence was 18/100,000 in children younger than 5 years and 1.1/100,000 in those 
children with measles after 5 years.10,11 It is caused by the cerebral involvement of the 
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measles virus, which causes destruction of the neurons. The 
pathogenesis of SSPE is yet to be elucidated, but it has been 
shown to be caused by the wild strains and not by the vac-
cine strains, which has been supported by genetic studies.12 
The strains of measles virus causing SSPE have multiple 
point mutations in their genomes, especially in the gene 
encoding for the matrix protein gene.13 Studies have shown 
that the capacity of wild-type measles virus strains to cause 
SSPE results from their increased capacity to spread and 
that this is partially due to a tri-residue motif, P64, E89, and 
A209 (PEA), in their M proteins, which is absent in vaccine 
and lab-adapted strains.14 Mutations in M proteins result in 
interference with the assembly of new viral particles and their 
budding, which form viral particles that are transmitted via 
ribonucleic protein with a trans-synaptic spread.15 Immaturity 
of the cellular immunity mechanism has been critical as sug-
gested by earlier age of acquiring measles infection resulting 
in higher incidences of SSPE.11 Although other viruses have 
been studied in association with SSPE, there is no data to 
support their role in causation of the disease.13
The worldwide prevalence of SSPE has declined to 1 
per 100,000 cases of measles due to better immunization 
coverage in developed countries.7 There is not only geo-
graphical variation in the prevalence of SSPE but economic 
development also contributes to the falling trends. Developed 
countries such as USA have reported an incidence of 6.5–11 
cases per 100,000 acute measles infections.12 European 
countries like Turkey have reported an incidence of 2.2 cases 
per million in their population.16 Developing countries like 
Pakistan have reported an estimated incidence of 10 cases 
per million in their population.17 The highest rate that has 
ever been reported is from Papua New Guinea, which is 51 
cases per one million during 2007–2009.18 Although there 
is no gender predisposition, but SSPE has been seen more 
commonly in boys.19 The risk of SSPE is higher if the onset 
of measles is at a younger age, in low socioeconomic class, 
in cases with low parental education and large family size.4
The clinical course is characterized by progressive 
cognitive decline and behavior changes followed by focal 
or generalized seizures as well as myoclonus, ataxia, visual 
disturbance, and later vegetative state.20,21 Patients suffering 
from SSPE die within few years of initial clinical presentation 
although there have been rare case reports of spontaneous 
remission.20 Epilepsy has been reported in one-third of the 
patients with SSPE.22
Jabbour et al23 have divided the clinical manifestations 
into four stages. Stage I is characterized by irritability, 
dementia, social withdrawal, lethargy, and regression of 
speech; stage II is characterized by various types of move-
ment disorders such as dyskinesia, dystonia, and myoclo-
nus. Stage III is consistent with extrapyramidal symptoms, 
decerebrate posturing, and spasticity, while the stage IV is 
characterized by loss of function of cerebral cortex with signs 
of vegetative state, autonomic failure, and akinetic mutism. 
Atypical presentations have been described including isolated 
psychiatric manifestations, poorly controlled seizures, and 
isolated extrapyramidal symptoms, such as dystonia, chorea, 
hemi-parkinsonism, etc. Occasionally, a stroke-like onset has 
also been described. There may be a transient plateau period 
or slight improvement in some patients, but classically it has 
a relentless pattern associated with high mortality.24 Differ-
ential diagnoses include epilepsy and psychiatric illnesses 
in early stages along with other viral encephalitides, atypical 
multiple sclerosis, leukodystrophies, variant Creutzfeldt–
Jakob disease, and neurometabolic encephalopathies.25 The 
diagnosis of SSPE is often considered late in developed 
countries owing to its rare occurrence and the nonspecific 
clinical manifestations at onset.26
Visual loss as an initial presentation has also been 
described.27 Ocular findings are seen in almost 50% of cases. 
A variety of neuro-opthalmological and retinal findings are 
associated with SSPE, and the classic lesion is focal necro-
tizing macular retinitis. There may be retinal hemorrhages, 
edema, and detachment. Vitreal inflammation is not seen in 
SSPE. Optic disc changes include papillitis, papilledema, 
and disc pallor. Retinal involvement may settle with time 
or eventually lead to scarring. Ophthalmic symptoms may 
precede the neurological symptoms of SSPE. Other symp-
toms that may occur include cortical blindness, gaze palsies, 
ptosis, and nystagmus.28
The diagnosis is based on the Dyken’s criteria, which 
include two major and four minor criteria. Major criteria 
include 1) raised anti-measles antibody titers in cerebrospi-
nal fluid (CSF) greater than or equal to 1:4 or ratio greater 
than or equal to 1:256 in serum, and 2) typical or atypical 
clinical history (typical includes acute or rapidly progres-
sive, subacute progressive, chronic progressive, and chronic 
relapsing–remitting, while atypical includes seizures, pro-
longed stage I, and unusual age of presentation that is either 
in infancy or adulthood). Minor criteria include the following: 
1) characteristic electroencepahlograhic findings that include 
periodic, generalized, bilaterally synchronous and symmetri-
cal high-amplitude slow waves that recur at regular intervals 
of 5–15 seconds called periodic slow-wave complexes also 
known as “Radermecker” complexes (Figure 1). The interval 
between complexes is generally fixed, but variation in the 
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interval between periodic discharges may also be seen, also 
known as pseudo-periodic or quasi-periodic discharges.29,30 2) 
CSF globulin levels greater than 20% of the total CSF protein. 
3) Characteristic histopathological findings on brain biopsy 
including inflammatory changes in the meninges and cerebral 
parenchyma necrotizing leukoencephalitis with diffuse demy-
elination; viral inclusion bodies in neurons; oligodendrocytes 
and astrocytes; neuronal loss; and astrocytosis. 4) Specialized 
molecular diagnostic test to identify wild-type measles virus 
mutated genome. Usually two major criteria plus one minor 
criterion are required, but if the features are atypical, then 
histopathological or molecular evidence may be required.29,30 
Interestingly, histopathological studies carried out after 
autopsy of individuals without SSPE showed approximately 
20% having detectable measles virus in the brain.31 However, 
just the presence of RNA without satisfaction of Dyken’s 
criteria would not mean that the person has SSPE.
Neuroimaging may be helpful but is not characteristic 
of SSPE. During the early stages, magnetic resonance (MR)
imaging of the brain may show decreased gray matter volume, 
especially within the frontotemporal cortex, amygdala, and 
cingulate gyrus. As the disease progresses, hyperintensities 
on T2-weighted images in the cerebral cortex, periventricu-
lar white matter, basal ganglia, and brainstem may develop 
(Figure 2A–C). Eventually, the MR images will reveal diffuse 
cortical atrophy, as evidenced by enlarged sulci and ventricu-
lomegaly. MR spectroscopy findings range from increased 
choline-to-creatinine ratio and inositol-to-creatinine ratios 
along with normal N-acetyl aspartate-to-creatinine ratios 
to decreased N-acetyl aspartate-to-choline and N-acetyl 
aspartate-to-creatinine ratio correlating to loss of brain vol-
ume (Figure 3A and B).19,32–36
Currently, there is no cure for SSPE, and eradication 
by effective vaccination program is considered to be more 
beneficial and cost-effective than any other high-level forms 
of control.6 Measles-containing vaccines are a part of the 
childhood vaccination schedule in all countries. Current 
World Health Organization (WHO) policy is that “Reach-
ing all children with 2 doses of measles vaccine should be 
standard for all national immunization programs”.37 Despite 
this, global coverage with the first dose of measles vaccine 
has largely stagnated since 2004. Six WHO regions have 
measles elimination goals for the year 2020, but the World 
Health Assembly has still not endorsed the eradication of this 
disease. In 2012, Measles and Rubella Initiative published 
a Global Measles and Rubella Strategic Plan 2012–2020, 
which aimed to achieve elimination of these two diseases in 
5 WHO regions by 2020. By the end of 2015, none of these 
milestones had been met. Although the number of countries 
with measles vaccine 1 coverage of >90% has risen between 
2010 and 2015, we are still a long way from a global measles 
eradication.37
Figure 1 EEG of a patient with SSPE.
Note: Longitudinal bipolar montage showing periodic slow waves also known as the 
“Radermecker” complexes.
Abbreviations: EEG, electroencephalogram; SSPE, subacute sclerosing panen­
cephalitis.
Figure 2 (A–C) The MRI of a 6­year­old girl with SSPE.
Notes: Abnormal signal intensity areas are identified in the periventricular and deep white matter region bilaterally. Abnormal signal are also noted in putamen bilaterally. 
These areas appear hyperintense on T2­weighted images, hypointense to isointense on T1­weighted images, and there is no evidence of diffusion restriction and no 
postcontrast enhancement.
Abbreviations: MRI, magnetic resonance imaging; SSPE, subacute sclerosing panencephalitis.
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Supportive treatment including management of seizures 
and other complications is the mainstay.11 Divalproate sodium 
is one of the common antiepileptics employed.38 There are no 
standard treatment protocols for the treatment of SSPE. Anti-
viral drugs and immunomodulators are used in the treatment of 
SSPE. Even though there are many drugs that have been tried 
in the treatment of SSPE, inosine pranobex, interferon alfa, 
ribavirin, and lamivudine are the most commonly used drugs 
in routine clinical practice. These have been used either singly 
or in combinations. Inosine pranobex (Isoprinosine, Inosiplex) 
is an antiviral drug with immunomodulatory effects. It is a 
synthetic compound. It is given orally in doses of 100 mg/kg/
day (with a maximum dose of 3,000 mg/day) in three divided 
doses to patients with SSPE. Abnormalities in serum and 
urinary uric acid and occasional nausea have been reported 
with Isoprinosine.39 Interferon alfa is an immunomodulator 
drug. It is preferably given via the intraventricular route as it 
has very poor penetration of the blood–brain barrier. Ribavarin 
and lamivudine have also been tried with no great success.
Ketogenic diet has also been tried; it was found to tempo-
rarily reduce the myoclonic jerks.40 Steroids and intravenous 
immunoglobulin  are no longer recommended for the treat-
ment of SSPE.
Future therapies are incorporating antiapoptotic agents, 
and RNAi is being experimented upon and may be beneficial 
in future.41
The prognosis for SSPE remains guarded. Mortality has 
been reported in 95% of the patients.42 The average life span 
of a patient suffering from SSPE is 3.8 years (45 days–12 
years).16 Another study has proposed that the mean survival 
in children is about 1 year 9 months to 3 years.11
Conclusion
In short, SSPE is a potentially lethal disease and causes 
a huge burden both emotionally and financially, affecting 
not only the family but the country as whole. Furthermore, 
as this is seen more in the underdeveloped countries, the 
economic burden to these nations is huge. There is a strong 
need to improve the vaccination status of countries where 
the incidence of measles is high as it may be the only way to 
eradicate this devastating condition. This requires a global 
and political will and ownership by the individual countries.
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